261 related articles for article (PubMed ID: 3605590)
1. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
2. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
Kronbach T
Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
[No Abstract] [Full Text] [Related]
3. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
4. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
6. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
8. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Leemann T; Bonnabry P; Dayer P
Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
[TBL] [Abstract][Full Text] [Related]
11. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.
Dayer P; Leemann T; Striberni R
Clin Pharmacol Ther; 1989 Jan; 45(1):34-40. PubMed ID: 2910636
[TBL] [Abstract][Full Text] [Related]
12. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
14. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Zanger UM; Vilbois F; Hardwick JP; Meyer UA
Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
[TBL] [Abstract][Full Text] [Related]
17. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
18. In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes.
Orishiki M; Matsuo Y; Nishioka M; Ichikawa Y
Int J Biochem; 1994 Jun; 26(6):751-8. PubMed ID: 8063004
[TBL] [Abstract][Full Text] [Related]
19. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
